Coyote Bioscience Co., Ltd. (“Coyote”) is a Chinese innovative high-tech company that has been engaged in molecular diagnostics for 10 years, and it especially excels at the fast nucleic acid detection technology for pathogenic microorganisms. Coyotes core technologies with independent intellectual property rights enable the company to participate in joint development in such interdisciplinary fields as related to instruments, reagents, system platforms, artificial intelligence and big data.
Coyote was founded in 2009, with its headquarters and R&D center in Beijing and an 8,000 square meter GMP production base in Yixing, Jiangsu Province. As a national high-tech enterprise and an experts base, the company has been awarded such honors as “Chinas Top 50 Most Valuable Enterprises for Investment”, “Chinas Most Promising Enterprise”, and “Advanced Collective” for combating the COVID-19 pandemic by the Ministry of Industry and Information Technology in 2020.
Coyote has applied for 83 domestic and international patents, mainly including 22 international PCT patents, 13 domestically authorized patents, 2 US patents and 1 Australian patent. It has participated in the Torch Program of the Ministry of Science and Technology and national major programs for infectious diseases. The corporate vision, “molecular diagnostics for everyone”, which has served as the source of Coyotes technological innovation in the past 10 years, is also its historical mission in the context of the normalized pandemic influence.